Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Core Insights - Lexicon Pharmaceuticals announced the publication of a research paper on its Phase 2 RELIEF-DPN-1 clinical trial for LX9211, aimed at treating diabetic peripheral neuropathic pain (DPNP) [1][3] Summary by Sections Clinical Trial Results - The RELIEF-DPN-1 study demonstrated that LX9211 provides clinically significant benefits for patients with DPNP, with a focus on pain relief over an 11-week evaluation period [7] - The primary efficacy endpoint was the change in average daily pain score (ADPS) from baseline to week 6, which was achieved in the low-dose LX9211 group [7] - Patient-reported outcomes improved significantly in those treated with LX9211, which was generally well tolerated [7] Current Treatment Landscape - Existing therapies for DPNP offer only modest pain relief, with less than 50% of patients achieving a 50% reduction in pain severity [2] - Many patients continue to use opioids as first-line therapy despite the associated high risks and complications, including mortality [2] Future Developments - The positive outcomes from the RELIEF-DPN-1 study support the initiation of Lexicon's larger Phase 2b PROGRESS trial, which is currently enrolling patients across the United States [3][15] - LX9211 has received Fast Track designation from the U.S. FDA for its development in DPNP, indicating its potential significance in addressing this medical need [11] Company Overview - Lexicon Pharmaceuticals is focused on pioneering innovative medicines, having launched INPEFA® (sotagliflozin) and developing a pipeline of drug candidates targeting neuropathic pain, diabetes, and metabolism [10] - The company utilizes its Genome5000™ program to identify therapeutic targets, having discovered over 100 protein targets with significant potential [10]